Related Experiment Videos
Human interleukin-4: an immunomodulator with potential therapeutic applications
1Lions Clinical Cancer Laboratory, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Australia.
Progress in Growth Factor Research
|January 1, 1991
Summary
Human interleukin-4 (IL-4) is a cytokine with anti-inflammatory and anti-cancer properties. Early studies show promise for IL-4 in treating hematological malignancies, with low doses being well-tolerated.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Human interleukin-4 (IL-4) is a cytokine produced by T cells.
- IL-4 influences immune responses, including B cell proliferation and immunoglobulin class switching.
- It exhibits anti-inflammatory and potential anti-cancer activities.
Purpose of the Study:
- To explore the therapeutic potential of IL-4.
- To investigate IL-4's effects on B cell neoplasms and its role in cancer therapy.
Main Methods:
- Review of existing literature on IL-4's biological effects.
- Analysis of in vitro studies on human tumor-infiltrating lymphocytes and B cell neoplasms.
- Examination of Phase I clinical trial data in cancer patients.
Main Results:
- IL-4 promotes IgE and IgG4 class switching and co-stimulates B cell proliferation.
- IL-4 has inhibitory effects on monocytes, suggesting anti-inflammatory potential.
- IL-4 demonstrates indirect anti-cancer activity and directly inhibits B cell neoplasm proliferation.
- Phase I trials show promising results in hematological malignancies with low, tolerated doses.
Conclusions:
- IL-4 possesses significant anti-inflammatory and anti-cancer properties.
- IL-4 is a promising therapeutic agent for hematological malignancies.
- Further clinical investigation of IL-4 in cancer treatment is warranted.